All In Biotech

Investigational drug · Phase 3

CC-99282

Also called: BMS-986369, Golcadomide

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

7 still active

All registered trials

23

Any phase or sponsor naming "CC-99282"

First trial start

2019

May 20, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CC-99282", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lymphoma, Follicular
  • Large B-cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Lymphoma, Non-Hodgkin
  • Follicular Lymphoma
  • Relapsed or Refractory T-cell Lymphomas

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "CC-99282" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Lymphoma, Follicular

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • AbexinostatPCI-24781Phase 35 trials

    Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.